Novo Nordisk stock pops on Ozempic kidney trial success

Yahoo Finance Video
1 年前

Shares of Novo Nordisk (NVO) rose on Wednesday after the drugmaker announced it was stopping a trial because early results show its popular diabetes drug Ozempic was effective in treating failure. The news sent kidney-dialysis stocks such as Fresenius Medical Care (FMS) and DaVita (DVA) plunging. Yahoo Finance Live discusses the popularity of the drug.

For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.